Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$12.54 - $46.93 $63,565 - $237,888
-5,069 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$45.28 - $74.5 $22,640 - $37,250
500 Added 10.94%
5,069 $211,000
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $66,843 - $98,698
1,169 Added 34.38%
4,569 $286,000
Q2 2021

Aug 13, 2021

BUY
$47.86 - $83.95 $162,724 - $285,430
3,400 New
3,400 $241,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $130M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Apg Asset Management N.V. Portfolio

Follow Apg Asset Management N.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apg Asset Management N.V., based on Form 13F filings with the SEC.

News

Stay updated on Apg Asset Management N.V. with notifications on news.